Lecanemab in Real-World Practice: What Early Alzheimer’s Patients Are Actually Experiencing Review Abstract Lecanemab represents a major milestone in the treatment of Alzheimer’s disease as the first anti amyloid monoclonal antibody to receive traditional approval from the United States Food and Drug Administration for patients with early
Tag: amyloid beta
Plasma Biomarkers for Neurodegenerative Disease: What Clinicians Need to Know in 2026
Plasma Biomarkers for Neurodegenerative Disease What Clinicians Need to Know in 2026 Review Key Takeaways Plasma biomarkers are rapidly transforming the diagnosis and management of Alzheimer’s disease and related dementias, representing one of the most notable advances in neurodegenerative medicine in recent decades. Historically, the definitive assessment of Alzheimer’s pathology has
Alzheimer’s Patients and Low Tau Burden Outcomes
Alzheimer's Patients and Low Tau Burden Outcomes Overview The study focuses on individuals within the Alzheimer's Disease (AD) pathway exhibiting abnormal amyloid-beta (Aβ) and tau deposition. Specifically, it investigates a subgroup characterized by low tau levels (A+T−) and compares them to their counterparts with higher tau levels (A+T+). The research involves 397 individuals
